TCRX Stock TCRX is expected to report earnings to fall -21% to -25 cents per share on May 07

A.I.dvisor
at Tickeron.com
05/06/24
Loading...
TCRX - TScan Therapeutics
TScan Therapeutics Earnings Graph
Q1'24
Est.
$-0.25
Q4'23
Beat
by $0.08
Q3'23
Beat
by $0.21
Q2'23
Beat
by $0.25
Q1'23
Missed
by $0.24
The last earnings report on December 31 showed earnings per share of -21 cents, beating the estimate of -29 cents. P/B Ratio (2.999) is normal, around the industry mean (10.296). P/E Ratio (0.000) is within average values for comparable stocks, (116.129). TCRX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.466). TCRX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.015). P/S Ratio (26.667) is also within normal values, averaging (233.055). With 88.68K shares outstanding, the current market capitalization sits at 452.51M.
View a ticker or compare two or three
TCRXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
830 Winter Street
Phone
+1 857 399-9500
Employees
154
Web
https://www.tscan.com